CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 335 · Search date 2026-07-11 · Methodology v0.6

Aster glehni extract powder,
does it really help with Improvement of age-related cognitive decline?

30-Second Summary
C
Evidence Grade C · 42 · Safety acceptable
This specific recognized ingredient was supported by submitted human evidence, but public cognitive clinical results and independent replication are lacking
What the
research shows
Aster glehni extract powder is a specific ingredient that passed an individual-recognition review including human evidence, but the sample, design, and cognitive efficacy results could not be verified in publicly available academic literature, and no independent replication was identified. It is therefore rated C. Published papers are mainly cellular or animal cognition studies, while a 12-week human trial for another indication did not test cognition.
What the
ads claim
Products may present improvement of age-related memory, concentration, and cognitive function, but the publicly identifiable evidence extends only to nonpublic human evidence submitted for the specific recognized ingredient.
*

Useful facts when choosing a product

  • The stated daily intake for the recognized ingredient is reported as 960 mg/day.
  • The cognitive claim applies to a specification-defined extract powder, not ordinary Aster glehni food.
  • Without a published cognitive clinical paper, the sample size and primary-endpoint details cannot be independently verified.
  • A 12-week human trial for another indication reported no adverse events or changes in safety parameters.
Gap Measurement · Verdict 335 · C 42
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Kang 2026 regulatory review lists Aster glehni extract powder as a Korean individually recognized ingredient for cognitive-function improvement and explains that human intervention evidence is part of an individual-recognition dossier. Liao 2019 reported improved memory behavior and signaling in mice with scopolamine-induced impairment, but it was not a human study. The 12-week Lee 2020 RCT assessed uric acid in mild hyperuricemia, found no between-group benefit at the final time point, and did not measure cognition.

02

Why this is classified as C (42)

The existence of a human trial is accepted from the individual-recognition process, while regulatory recognition itself is not used as efficacy evidence. With no public results or independent replication and evidence concentrated in an applicant-specific ingredient, the rating is low C at 45 points.

Counterpoint. A cognitive signal may remain possible for the specific standardized ingredient, but extrapolation to ordinary Aster glehni or other extracts is a separate issue.

Rejudgment record. New judgment — Human evidence for individual recognition exists, but public cognitive clinical results and independent replication are lacking and evidence is concentrated in an applicant-specific ingredient

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kang P et al. 2026Review of the regulatory system and individually recognized ingredientsKorean government research supportClassification of individually recognized ingredients and dossier evidence requirementsListed Aster glehni extract powder as an individually recognized cognitive ingredient and described the requirement for human intervention evidence.Confirms existence of human evidence; effect size unknown
Liao Y et al. 2019Preclinical study in mice with scopolamine-induced cognitive impairmentIncluded authors from the Koreaeundan R&D centerWater maze, passive avoidance, Y-maze, AChE, and signaling proteinsReported improvement in memory behavior and selected signaling pathways.Preclinical, manufacturer-linked
Lee S et al. 2020Randomized double-blind placebo-controlled trial for another indicationMultiple authors were affiliated with KoreaeundanUric acid, xanthine oxidase, inflammatory markers, and safetyNo between-group uric-acid benefit was found at 12 weeks, and no adverse events or safety-parameter changes were reported. Cognition was not measured.Supportive for safety, outside the efficacy claim
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Kang P, Kim SY, Shi J, Choi YH, Chin YW. Individually Recognized Functional Ingredients of Korean Health Functional Foods: Functional Classification, Regulatory Context, and Clinical Implication. Nutrients. 2026;18(4):637. PMID: 41754154. DOI: 10.3390/nu18040637.
checked
Liao Y, Bae HJ, Park JH, Zhang J, Koo B, Lim MK, Han EH, Lee SH, Jung SY, Lew JH, Ryu JH. Aster glehni Extract Ameliorates Scopolamine-Induced Cognitive Impairment in Mice. J Med Food. 2019;22(7):685-695. PMID: 31225769. DOI: 10.1089/jmf.2018.4302.
checked
Lee S, Han EH, Lee SH, Lim MK, Kim CO, Kang S. Effects of Aster glehni Extract on Serum Uric Acid in Subjects with Mild Hyperuricemia: A Randomized, Placebo-Controlled Trial. J Med Food. 2020;23(5):508-514. DOI: 10.1089/jmf.2019.4513.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Aster glehni extract powder x improvement of age-related cognitive decline Evidence Grade C card
[Chamgap] Aster glehni extract powder x improvement of age-related cognitive decline — Evidence Grade C·42. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/cognition/aster-glehni-age-related-cognition/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.